



**NORTH CAROLINA
MEDICAL BOARD**

Cheryl L. Walker-McGill, MD
President

Pascal O. Udekwu, MD
President-Elect

Eleanor E. Greene, MD
Secretary/Treasurer

1203 Front Street
Raleigh, North Carolina 27609-7533

Mailing:
P.O. Box 20007
Raleigh, North Carolina 27619-0007

Telephone: (919) 326-1100
Fax: (919) 326-1131
Email: info@ncmedboard.org
Web: www.ncmedboard.org

January 14, 2015

Via Certified Mail – Return Receipt Requested

Anthony Vernon Dallas, Jr., M.D.
Family Healthcare of Hendersonville
353 New Shackle Island Road, Suite 141C
Hendersonville, TN 37075

Dear Dr. Dallas:

The North Carolina Medical Board (“Board”) has reviewed information regarding the action taken against your Mississippi medical license by the Mississippi State Board of Medical Licensure (“Mississippi Board”) and has decided to issue you this public letter of concern pursuant to N.C. Gen. Stat. §90-14(a)(13).

On September 4, 2014, you entered into a Consent Order with the Mississippi Board of Medical Licensure (Mississippi Board) based on allegations that you: (1) failed to obtain a Registration Certificate issued by the U.S. Drug Enforcement Administration for Mississippi prior to placement of orders of controlled substances for the purpose of prescribing, administering or dispensing of controlled substances; (2) delegated the authority to dispense controlled substances by virtue of your medical license; (3) administered, dispensed or prescribed a narcotic drug or other drug having addiction-forming or addiction-sustaining liability otherwise than in the course of legitimate professional practice. As a result, your Mississippi medical license was suspended for three months and placed on probation for one year. You were required to attend continuing medical education courses on proper prescribing of medications and medical ethics and you were required to pay investigative costs.

The Board notes that allegations that form the basis of the Mississippi Consent Order stem from your responsibilities as Chief Medical Officer of a company that provides on-site healthcare services through employers. As Chief Medical Officer, you oversee healthcare services provided by the company across the country.

The Board notes that your company has a policy that prohibits controlled medications in your formularies and that Tramadol had been ordered under your name and license as part of pre-packaged, non-controlled medications. These medications were to be on hand to be available when a clinic opened, and, as required by company policy, were to be transferred to another licensed provider there at the clinic prior to being dispensed. We understand that, at one point, Tramadol was changed from a non-controlled substance to a controlled substance under state law and neither you nor your company received notice of this change. We recognize that the Tramadol was dispensed by a licensed nurse practitioner (with prescriptive authority) under the supervision of another physician. Nevertheless, because the Tramadol

Anthony Vernon Dallas, Jr., M.D.
January 14, 2015
Page Two

previously had been ordered under your name and license, you ultimately were held responsible by the Mississippi Board. We further recognize that your company has changed its policies and audit procedures to avoid a repetition of the foregoing events.

The action by the Mississippi Board, which is the first disciplinary action against your license in thirty-five years of practice, was based on your failure to navigate Mississippi's regulatory framework and comply with Mississippi state law. Importantly, there was no allegation of patient harm.

The Board cautions you that repetition of similar occurrences may lead to the commencement of disciplinary proceedings against your license to practice as a physician in North Carolina. In such an event, this public letter of concern may be entered into evidence as aggravation. This public letter of concern shall become a public record within the meaning of Chapter 132 of the North Carolina General Statutes and shall be subject to public inspection and dissemination pursuant to the provisions thereof. Additionally, it will be reported to persons, entities, agencies and clearinghouses as required by law.

Sincerely,



Cheryl L. Walker-McGill
Board President

CWM/BB/bjs